Key Highlights

  • The net loss was USD 86.7 million compared with USD 812.7 million in the third quarter of 2025.
  • Cash, cash equivalents and marketable securities were USD 481.6 million, funding operations into early 2029.
  • Research and development expense rose USD 20.4 million, including USD 11.8 million for new telitacicept programs.
  • Enrollment in the Phase 3 Upstream MG trial was completed in September 2026, and a new ocular trial is planned.

Net Loss Narrows From a Large Prior-Year Charge

Vor Biopharma Inc. (NASDAQ:VOR) reported a third-quarter 2026 net loss of USD 86.7 million compared with USD 812.7 million a year earlier. Other expense, net decreased by USD 756.3 million, which accounts for almost all of the improvement. For nine months, the net loss was USD 369.1 million versus USD 2,418.8 million.

The company noted that it has incurred significant operating losses since inception.

General and administrative expenses were USD 23.9 million versus USD 14.0 million. The increase in stock-based compensation was primarily driven by grants to new management team members hired in the second and third quarters of 2025, an appreciation in the stock price and incremental expense from award modifications at the end of 2025.

Research and development expense rose USD 20.4 million, primarily from an aggregate USD 11.8 million increase in spending on the new telitacicept programs in generalized myasthenia gravis and Sjogren's disease, a USD 5.5 million increase in salaries and benefits from growth in Research and Development headcount and a USD 2.3 million increase in other research costs. External research spending on telitacicept for generalized myasthenia gravis was USD 17.1 million versus USD 13.1 million.

Telitacicept Programs

Telitacicept, licensed from RemeGen, is being evaluated in the global Phase 3 UPSTREAM MG trial for generalized myasthenia gravis, for which the company assumed responsibility, and enrollment was completed in September 2026. RemeGen separately ran a Phase 3 trial in China, with 48-week Part B data presented at the American Association of Neuromuscular and Electrodiagnostic Medicine annual meeting in October 2025.

In September 2026 the company announced plans for a registrational global Phase 3 trial in ocular myasthenia gravis, UPSTREAM oMG, with enrollment anticipated to begin in the first half of 2027. It is also evaluating telitacicept in the global Phase 3 UPSTREAM SjD trial in Sjogren's disease, and 48-week Stage A and B data from the RemeGen trial were presented at the American College of Rheumatology meeting in October 2025.

Cash Runway and Risks

Cash, cash equivalents and marketable securities totaled USD 481.6 million at September 30, 2026, and under the current operating plan the company expects them to fund operating expenses and capital expenditures into early 2029. The company identified dependence on telitacicept as a key risk, along with reliance on data generated by RemeGen and third parties and uncertainty over whether data from trials run by RemeGen are accepted by regulators. Results and data from RemeGen trials may be limited or delayed, and the company depends on third parties to generate and report data accurately.

Trial Milestones Ahead

Items to watch include UPSTREAM MG data timing, the start of UPSTREAM oMG enrollment, research spending growth and cash burn against the runway.